Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 370 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 39 Publications

9 Customer Reviews

  • (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

    OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    T47D breast cancer cells were pretreated with indicated concentrations of ABT-888

     

     

    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

    Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.

     

     

    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

  • Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     
     

     

    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 MmjuT4lv[XOnIFHzd4F6 MYCzNEBucW5? NFHCZ41KdmirYnn0bY9vKG:oIGDBVnAyKHerdHigSWM2OCCxZjCwMlAxOiEQvF2= MWixPVg5QDd4MB?=
Jurkat NUDjclhpU2mwYYPlJGF{e2G7 MX25OkBp NGDwT|RFVVOR MW\Jcohq[mm2aX;uJI9nKFCDUmCxJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDj[YxtKH[rYXLpcIl1gSC5aYToJGVEPTBib3[gN{DPxE1? M4HkelI{QDVyMUm5
Capan1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWC3NkBp NVv5NWNHTE2VTx?= Mo\mRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDCVmNCOiCpZX7lJI12fGG2ZXSgbJVu[W5iQ3HwZY4yKGOnbHzzJJdqfGhiSVO1NEBw\iB|OT63JO69VQ>? MX2yOFM6QDN6Mx?=
DT40 NGmyO4REgXSxdH;4bYMhSXO|YYm= NEXXVY84OiCq NVnK[IxnTE2VTx?= NWn3UJlzS3m2b4TvfIlkcXS7IHHnZYlve3RiY3jpZ4tmdiCEUlPBNk1l\W[rY3nlcpQhTFR2MDDj[Yxtew>? M4PPR|I1QTJ{NUi3
ML-1 MXvBdI9xfG:2aXOgRZN{[Xl? NVPMNm97Oi53IN88US=> MWGyOEBp NEjUc5hFVVOR M{nUeXN6dmW{Z3nzeIlk[WyueTDlcohidmOnczDUVmFKVC2rbnT1Z4VlKGGyb4D0c5NqeyCrbjDNUE0yKGOnbHzz M2Ozd|I1QDl3MUO1
HCT-116 NWDvSpI1U2mwYYPlJGF{e2G7 M2nlfVAvPSEQvF2= MWSyOEBp NVjxem9qWEGUUDDhZ5Rqfmm2eTDk[YNz\WG|ZYO= M3nwU|I{ODV2MkGz
UM-SCC1 MULDfZRwfG:6aXOgRZN{[Xl? MYCxNEDPxE1? Mo\INlQhcA>? NEfKUnJT\WS3Y3XzJJRp\SClZXzsJJZq[WKrbHn0fS=> MUKyNVkyOjZ{MB?=
FaDu MWHDfZRwfG:6aXOgRZN{[Xl? NHroRoUyOCEQvF2= MV[yOEBp M4PETXJm\HWlZYOgeIhmKGOnbHygeoli[mmuaYT5 NIXvbVczOTlzMk[yNC=>
PC-3 NHOxb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVWxNEDPxE1? M{HIVmlv\HWlZYOgZUB{cWewaX\pZ4FvfCCrbnjpZol1cW:wIHnuJINwdG:weTDmc5Ju[XSrb39CpC=> MnXqNlE2PzF7MUK=
EoL-1-cell M3jpNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTFwMEe5PEDPxE1? NG\pTZhUSU6JRWK=
NCI-SNU-5 MlnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fXOWlEPTB;Mz6xNlg1OSEQvF2= MU\TRW5ITVJ?
BV-173 M{DBRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XiU2lEPTB;NT60OVQxQSEQvF2= NFznN49USU6JRWK=
HCC1806 M{fYN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;O[2lEPTB;NT63OVE4OyEQvF2= Mn7tV2FPT0WU
COLO-680 NYXpUoNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPYVVdjUUN3ME22MlIyPDB4IN88US=> M2ezRnNCVkeHUh?=
HCC2218 NELOeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzzcI44UUN3ME23Mlc6PzB2IN88US=> NUS2fm9IW0GQR1XS
SK-MEL-24 NUPvW2tqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDEUXBKSzVyPUeuPFE6OjRizszN NVXGVJNoW0GQR1XS
NCI-H720 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoezTWM2OD16LkSzOlA{KM7:TR?= NWC3W2M2W0GQR1XS
KASUMI-1 NYXuOHFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRThwOEmyOlYh|ryP M1nZbnNCVkeHUh?=
HAL-01 NVfYOGE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTlwOEi2NkDPxE1? MkjyV2FPT0WU
CAL-33 NHPaW|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTFyLkSzOEDPxE1? NXm0S416W0GQR1XS
SK-MEL-1 NXnGVIxET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTF{LkS2OlMh|ryP M2PZc3NCVkeHUh?=
Ramos-2G6-4C10 NIn0eW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLjTWM2OD1zMj60O|UzKM7:TR?= M2Lj[3NCVkeHUh?=
KY821 NUPpW|N7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfaTWM2OD1zMj60PFUh|ryP NIDjSYZUSU6JRWK=
HEC-1 NW\GUJg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TWRmlEPTB;MUKuPVE6PiEQvF2= NHHhPGNUSU6JRWK=
SK-NEP-1 Ml\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\FcYlGUUN3ME2xN{4yPjZizszN NFz2cnJUSU6JRWK=
MN-60 NXzCc41HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTF|LkWzPFkh|ryP NGPobnpUSU6JRWK=
DU-145 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH4VYFqUUN3ME2xN{46ODV|IN88US=> MmLaV2FPT0WU
EW-3 NHPoXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfXRYNKSzVyPUG0MlU2PjVizszN MWDTRW5ITVJ?
OS-RC-2 M4n6XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjh[ZFKSzVyPUG1Mlk2QDlizszN NEHYU5hUSU6JRWK=
RPMI-8226 NXn3dmQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTF4LkKwOFIh|ryP Mmr1V2FPT0WU
ChaGo-K-1 MmHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXkdXhKSzVyPUG2MlU{OjVizszN NV3WN2JVW0GQR1XS
DEL NFvXWXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTF4Lk[3NVch|ryP NVrUVHVsW0GQR1XS
GP5d NGGzWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfyTWM2OD1zNz6wOVMh|ryP Ml7TV2FPT0WU
COLO-668 MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXiTWM2OD1zNz62Nlk1KM7:TR?= NHnxO|FUSU6JRWK=
H9 NV22epRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLYTWM2OD1zOD6yPFM{KM7:TR?= MUHTRW5ITVJ?
NKM-1 NX3TV2NqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Xye2lEPTB;MUiuOVEyQSEQvF2= MVvTRW5ITVJ?
KYSE-150 NF3IPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfkTWM2OD1zOD65PVg3KM7:TR?= NIrWRoJUSU6JRWK=
Daoy MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr3TWM2OD1zOT61OlQ6KM7:TR?= NWqydJk1W0GQR1XS
ECC10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;oTWM2OD1{MD63OFU2KM7:TR?= NXLrZmViW0GQR1XS
A388 M4jKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC0dXRyUUN3ME2yNU46ODlzIN88US=> MVfTRW5ITVJ?
MHH-NB-11 Mm\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIOyTWhKSzVyPUKzMlE{PjNizszN NIe4eIZUSU6JRWK=
HCC1937 NX7zU3hGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJ2Lke0OkDPxE1? MXzTRW5ITVJ?
TGBC11TKB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJ3Lk[4OlMh|ryP MnG3V2FPT0WU
CTV-1 Mm\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE[yUI9KSzVyPUK1Mlg6PjlizszN NX\3epZoW0GQR1XS
NCI-H2029 M{HhS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjuTWM2OD1{Nj60NlM5KM7:TR?= M{fqbHNCVkeHUh?=
HLE NILwRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvObnZKSzVyPUK3MlA2PCEQvF2= MoPjV2FPT0WU
NCI-H1693 NGroZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXBTWM2OD1{Nz6yPFk5KM7:TR?= M3P1THNCVkeHUh?=
HCC70 NIDxdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\ue2lEPTB;MkeuO|I1PiEQvF2= MXvTRW5ITVJ?
BEN MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj5TWM2OD1{Nz65OVY3KM7:TR?= MkOwV2FPT0WU
LB771 NHjt[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjLcFQ2UUN3ME2yPE45Ozd|IN88US=> NHH2[|RUSU6JRWK=
697 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PVUWlEPTB;MkmuNFI{PSEQvF2= NInjT25USU6JRWK=
LU-139 MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XhZmlEPTB;MkmuN|c1QCEQvF2= MUjTRW5ITVJ?
EW-13 NFmwXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXzTWM2OD1{OT6zPFE1KM7:TR?= MkDIV2FPT0WU
MOLT-13 M3P2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjVTlR6UUN3ME2yPU4{QDF2IN88US=> M2jINHNCVkeHUh?=
L-363 NYnOU|c2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGX4WpdKSzVyPUK5MlQ4QThizszN NGL1R4dUSU6JRWK=
EM-2 NUP0V2ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTJ7LkS5NFEh|ryP MXLTRW5ITVJ?
RS4-11 M{PiSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\lWmlEPTB;M{CuOFI1OSEQvF2= M{[4c3NCVkeHUh?=
A2780 NFTSOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTNyLke0OVch|ryP NHi1fGlUSU6JRWK=
KU812 M2e5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D1XWlEPTB;M{KuN|Y1OiEQvF2= MkLnV2FPT0WU
COLO-684 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\1TWM2OD1|Mz6zOVk6KM7:TR?= MXjTRW5ITVJ?
MFE-280 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPxTWM2OD1|Mz6zPFg6KM7:TR?= NGTUUHBUSU6JRWK=
KG-1 NHizNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrxNm5KSzVyPUOzMlYxODFizszN NXnCbVZ[W0GQR1XS
JVM-3 NE\4ZndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTN3LkW4Olgh|ryP NFnGZ2JUSU6JRWK=
MV-4-11 NUnJVnVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLOXpBNUUN3ME2zOU45PDl7IN88US=> MXLTRW5ITVJ?
LAMA-84 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn3TWM2OD1|Nj63N|Q2KM7:TR?= MmrkV2FPT0WU
MOLT-16 NXK0UJdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTpSWlKSzVyPUO2Mlk2OiEQvF2= M4XuZXNCVkeHUh?=
H4 NFPEPYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M132NmlEPTB;M{euOVY4KM7:TR?= NVW1eI94W0GQR1XS
T47D NHrEdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33RWGlEPTB;M{euO|AyQCEQvF2= Ml3rV2FPT0WU
CAL-54 NIjmd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOwN|dSUUN3ME2zO{46PjZizszN MWHTRW5ITVJ?
SW982 NH30NXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL6TWM2OD1|OD6wPVk5KM7:TR?= M2\FcHNCVkeHUh?=
IGROV-1 M2DIeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXRdFVKSzVyPUO5MlM{ODRizszN NU\aVnhXW0GQR1XS
NB14 MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorFTWM2OD12MD63NFMyKM7:TR?= MV7TRW5ITVJ?
HCC1187 NUfibGQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDFNGdKSzVyPUSxMlI4PzFizszN MYnTRW5ITVJ?
SBC-1 NYHsXXRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFmwN4FKSzVyPUSxMlMxPjNizszN MWfTRW5ITVJ?
KARPAS-45 M{jzXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH2cZNKSzVyPUSxMlQ5OThizszN MkPUV2FPT0WU
MOLT-4 NV7tfFIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LldmlEPTB;NEKuNlU{QCEQvF2= MXvTRW5ITVJ?
JVM-2 MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnncpVRUUN3ME20Nk46OjB5IN88US=> Mn73V2FPT0WU
A4-Fuk M1T2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:0eoZ1UUN3ME20N{42PjlzIN88US=> M{TZdXNCVkeHUh?=
MDA-MB-361 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrXPYdKSzVyPUSzMlg1OTRizszN NYjOTWpbW0GQR1XS
BALL-1 NVnBbWt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLqcY5rUUN3ME20N{46PTN{IN88US=> NEL4OWRUSU6JRWK=
T98G M{[5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfWTWM2OD12ND64OVE4KM7:TR?= NHLnd|lUSU6JRWK=
Mo-T MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfCeHJwUUN3ME20OU43Ozh7IN88US=> NEfFcJpUSU6JRWK=
MHH-PREB-1 MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTR3Lke1PFUh|ryP MYXTRW5ITVJ?
ALL-PO NEjQTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLJTWM2OD12Nz6zO|kyKM7:TR?= NVPsdWExW0GQR1XS
NCI-H510A MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LuTWlEPTB;NEeuPVA{PCEQvF2= M{DUV3NCVkeHUh?=
ML-2 NGDuUmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPpTWM2OD12OT63PFU3KM7:TR?= MkDSV2FPT0WU

... Click to View More Cell Line Experimental Data

In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research
+ Expand
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Formulation: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 0.5% methylcellulose+0.2% Tween 80 5 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02849496 Not yet recruiting BRCA1 Gene Mutation|BRCA2 Gene Mutation|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma National Cancer Institute (NCI) May 2017 Phase 2
NCT02831179 Not yet recruiting Functional Pancreatic Neuroendocrine Tumor|Malignant Somatostatinoma|Merkel Cell Carcinoma|Metastatic Adrenal Gland Pheochromocytoma|Metastatic Carcinoid Tumor|Multiple Endocrine Neoplasia Type 1|Multiple Endocrine Neoplasia Type 2A|Multiple Endocrine Neoplasia Type 2B|Neuroendocrine Neoplasm|Non-Functional Pancreatic Neuroendocrine Tumor|Pancreatic Glucagonoma|Pancreatic Insulinoma|Recurrent Adrenal Cortex Carcinoma|Recurrent Adrenal Gland Pheochromocytoma|Recurrent Merkel Cell Carcinoma|Somatostatin-Producing Neuroendocrine Tumor|Stage III Adrenal Cortex Carcinoma|Stage III Thyroid Gland Medullary Carcinoma|Stage IIIA Merkel Cell Carcinoma|Stage IIIB Merkel Cell Carcinoma|Stage IV Adrenal Cortex Carcinoma|Stage IV Merkel Cell Carcinoma|Stage IVA Thyroid Gland Medullary Carcinoma|Stage IVB Thyroid Gland Medullary Carcinoma|Stage IVC Thyroid Gland Medullary Carcinoma|Thymic Carcinoid Tumor|VIP-Producing Neuroendocrine Tumor|Well Differentiated Adrenal Cortex Carcinoma|Zollinger Ellison Syndrome Vanderbilt-Ingram Cancer Center|National Cancer Institute (NCI) August 2016 Phase 1
NCT02631733 Recruiting Estrogen Receptor Negative|HER2/Neu Negative|Neuroendocrine Neoplasm|Progesterone Receptor Negative|Stage IIB Cervical Cancer|Stage IIIA Cervical Cancer|Stage IIIB Cervical Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIC Breast Cancer|Stage IV Breast Cancer|Stage IV Cervical Cancer|Stage IV Gastric Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Ovarian Cancer|Stage IV Small Cell Lung Carcinoma|Triple-Negative Breast Carcinoma National Cancer Institute (NCI) July 2016 Phase 1
NCT02595905 Recruiting BRCA1 Mutation Carrier|BRCA2 Mutation Carrier|Estrogen Receptor Negative|HER2/Neu Negative|Progesterone Receptor Negative|Stage IV Breast Cancer|Triple-Negative Breast Carcinoma National Cancer Institute (NCI) July 2016 Phase 2
NCT02723864 Recruiting Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 2016 Phase 1
NCT02483104 Active, not recruiting Ovarian Cancer AbbVie July 2015 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID